Le Lézard
Classified in: Health
Subject: SVY

Breast Biopsy Market Expected to Reach $1,420 Million by 2023 - Allied Market Research



PORTLAND, Oregon and PUNE, India, October 6, 2017 /PRNewswire/ --

According to a new report published by Allied Market Research titled, Breast Biopsy Market by Product and End User - Global Opportunity Analysis and Industry Forecast, 2017-2023, the global breast biopsy market was valued at $977 million in 2016, and is projected to reach at $1,420 million by 2023, growing at a CAGR of 5.3% from 2017 to 2023. Core needle biopsy (CNB) segment accounted for about half of the global market share in 2016.

A breast biopsy is the procedure of locating a diseased tissue in the breast and collecting the specimen sample of the area for further examination and diagnosis. Breast biopsies are performed by using minimally invasive biopsy systems, owing to minimal disfigurement and pain. Non-invasive biopsy techniques provide preventive measures that assist physicians in diagnosing and treating high-risk breast cancer. This information prevents the application of chemotherapy in breast cancer, reducing the complexities of chemo-radiations. Vacuum assisted breast biopsy devices (VAB), core needle biopsies and fine needle aspiration biopsy are commonly used to perform biopsy procedures.

Do Enquiry for Sample Report@ https://www.alliedmarketresearch.com/request-sample/1067

The major factors that boost the market growth include rise in incidence of breast cancer, growth in awareness toward cancer screening programs, and increase in demand for minimal invasive breast biopsies. Moreover, the ongoing technological advancements of diagnostic and treatment technology for breast cancer have undergone a gradual transition from open surgery to minimal invasive biopsy procedures. Breast cancer is the most common type of cancer in women, especially in the U.S., where it is the second leading cause of death propels the demand for breast biopsy procedures. Furthermore, requirement of robust measures for disease control, the thrust for newer technologies has led to the development of minimal invasive surgeries. This has made breast biopsy as preferred modality to diagnose breast cancer and identify complex tumors and make accurate diagnosis. However, lack of awareness toward the availability of novel breast biopsy techniques and risk of infection involved in the procedures are projected to hamper the market growth.

The core needle biopsy (CNB) segment dominated the global market in 2016, and is expected to maintain this trend throughout the analysis period, owing to the less invasive procedure compared to others and it provides more definitive diagnosis. Moreover, use of CNB and ultra sonographic and mammographic guidance is highly accurate for diagnosing breast cancer that supplements the market growth.

The ultrasound guided biopsy is poised to grow at the highest rate during the forecast period, owing to the sound waves used instead ionizing radiation to locate abnormality or lump and is less invasive in nature with reduced scars. Ultrasound guided biopsy segment is expected to grow at a high CAGR of 6.1% from 2017 to 2023.

Do Enquiry before purchasing Report@ https://www.alliedmarketresearch.com/purchase-enquiry/1067

Asia-Pacific is anticipated to grow at a highest rate throughout the analysis period, owing to the continuous growth in countries, such as Japan, India, China, and Australia. For instance, in Japanese women between the age group of 30-64, breast cancer is one of the leading cancer types over the past decade. In addition, as per Japanese Society of Breast Health, one in every 20 women are diagnosed with breast cancer in Japan. This is a clear trend toward the increase in demand for breast biopsy procedures for screening and diagnosis of breast cancer at early stages. Furthermore, commandment by the government bodies for routine screening for breast cancer after the age of 40 for women has raised the demand for breast biopsy devices. Technological advancements for cost-effective devices in these nations offer a lucrative opportunity for the breast biopsy market growth.

Key Findings of the Breast Biopsy Market:


Key players operating in the market include Hologic Inc., Leica Biosystems Nussloch GmbH (Devicor Medical Products, Inc.), C. R. Bard, Inc., Becton and Dickinson Company, Argon Medical Devices, Cook Medical Incorporated, Encapsule medical Devices LLC., Ethicon Endo Surgery (Johnson & Johnson), Intact Medical Corporation, and Galini SRL.

Ask for discount before buying@ https://www.alliedmarketresearch.com/get-discount/1067

About Us:

Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.


Contact:
Dhananjay Potle
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free: +1-800-792-5285
UK: +44-845-528-1300
Hong Kong: + 852-301-84916
India (Pune): +91-20-66346060
Fax : +1?855?550-5975
help@alliedmarketresearch.com

Web: https://www.alliedmarketresearch.com  

SOURCE Allied Market Research


These press releases may also interest you

at 17:27
Six provinces, 20 community pharmacy companies on board with PrescribeITtm  TORONTO, Oct. 19, 2017 /CNW/ - PrescribeITtm, Canada's national e-prescribing service, is continuing to demonstrate momentum with the addition of even more community...

at 17:23
BETHESDA, Md., Oct. 19, 2017 /PRNewswire/ -- Quality Care Properties, Inc. (NYSE: QCP) ("QCP" or the "Company") announced today that it has agreed with HCR ManorCare, Inc. and HCR III Healthcare, LLC, the Company's principal tenant (collectively,...

at 17:16
SYRACUSE, N.Y., Oct. 19, 2017 /PRNewswire/ -- Bankers Healthcare Group, the leading provider of financial solutions for healthcare professionals, has been named one of the 2017 Best Medium Workplaces by Great Place to Work® and FORTUNE magazine....

at 17:06
BERKELEY, Calif., Oct. 19, 2017 /PRNewswire/ -- Jmîchae?e Keller, President and CEO of Steep Hill, the global leader in cannabis science, testing and analytics, offered Steep Hill's support to the 2017 California fire victims and their families. "We...

at 17:03
RICHMOND HILL, ONTARIO--(Marketwired - Oct. 19, 2017) - Helix BioPharma Corp. (TSX:HBP)(FRANKFURT:HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today...

at 17:00
CHICAGO and Tampa, Fla., Oct.19, 2017 /PRNewswire/ -- Harmony Health Plan, Inc. ("Harmony"), a subsidiary of WellCare Health Plans, Inc. (NYSE: WCG), announced today it signed a contract with the Illinois Department of Healthcare and Family Services...




News published on 6 october 2017 at 06:45 and distributed by: